8 executives of well-known pharmaceutical companies resigned

On April 15, Hainan Haiyao issued an announcement stating that the board of directors received a written resignation report from some senior executives on April 14.

According to the announcement, Zhao Yuexiang, a director and executive deputy general manager of Hainan Haiyao, applied to resign from the post of executive deputy general manager due to personal reasons.

In addition to Zhao Yuexiang, Hainan Haiyao’s announcement shows that there are seven other deputy general managers whose positions have changed.

Deputy General Managers Lin Jian, Wang Wei, Bai Zhiquan, Li Gang, and Wang Weiqin applied to resign from the post of Deputy General Manager due to work adjustments, and Deputy General Manager Chen Guie applied to resign from the post of Deputy General Manager due to reaching retirement age.

After resignation, Lin Jian, Wang Wei, Bai Zhiquan, Li Gang, Wang Weiqin, and Chen Guie continued to hold other positions in Hainan Haiyao.

The aforesaid resignation report shall take effect from the day when it is delivered to the board of directors of Hainan Haiyao.

This is the second time Hainan Haiyao has issued an announcement related to high-level personnel changes since 2021.

On January 30, Hainan Haiyao announced that it had received written resignation reports from Chairman Cheng Aimin and Vice Chairman and General Manager Liu Xicheng.

Cheng Aimin applied to resign as chairman, director, convener of the strategy committee of the board of directors, and member of the nomination committee due to work adjustments.

Subsequently, Hainan Haiyao announced that Pan Dazhong was the chairman of the tenth board of directors and appointed Cai Haojie as the general manager.

Affected by the epidemic, performance has declined

Hainan Haiyao is a long-established Hainan pharmaceutical manufacturing company with profound background.

On April 15, Hainan Haiyao released the 2020 annual performance report and the first quarter performance forecast of 2021.

The net profit loss in the first quarter of this year is estimated to be between 120 million yuan and 180 million yuan, a decrease of 18.

According to the performance bulletin, Hainan Haiyao’s loss was due to factors such as the impact of the new crown epidemic, the decline in antibiotic demand, the increase in raw material costs, the high investment in research and development costs, and the large amount of impairment provisions.

In fact, Hainan Haiyao has been deducting non-net profits for 4 consecutive years at a loss-from 2017 to 2019, Hainan Haiyao has deducted non-net profits of -24.

Faced with the decline in performance, Hainan Haiyao actively transformed its response.

It is understood that in the future, Hainan Haiyao will rely on the resources of central enterprises to lock in the "three highs" and "four specials" (high-end biopharmaceuticals, high-end medical devices, high-end preparations, special anti-infective drugs, special military medicines, special Chinese medicines, and neuropsychiatrics.
And the strategic development direction of specialty medicines such as children and the elderly), and further focus on the main business.

In addition, in the 2020 semi-annual report, Hainan Haiyao specifically mentioned that in June 2020, the central government issued the "Overall Plan for the Construction of Hainan Free Trade Port".
As one of the key industries supported by Hainan Free Trade Port, the company will Usher in historical development opportunities.
The company will take advantage of the opportunity of building Hainan Free Trade Port and Boao Lecheng International Medical Tourism Pioneer Zone, give full play to its advantages in the Hainan base, clarify strategic goals, focus on the main business, transform to cutting-edge, high-end, and distinctive development, and take the path of differentiated development.
.

On April 8, 2021, the National Development and Reform Commission and the Ministry of Commerce issued the "Opinions on Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access.
" On April 12, the State Council Information Office held a press conference on the progress of the Hainan Free Trade Port policy system.
Cong Liang, deputy director of the National Development and Reform Commission, introduced that the construction of Hainan Free Trade Port has further accelerated.

In the future, it remains to be seen whether Hainan Haiyao can seize the policy dividend and reverse the past decline.

Under industry pressure, medical professionals are facing transformation

In fact, the flow of senior management personnel in pharmaceutical companies has been relatively frequent.

Shi Lichen, the founder of Beijing Dingchen Pharmaceutical Management Consulting Center, pointed out to Cyberland that the resignation of senior executives of pharmaceutical companies is often divided into personal reasons and non-personal reasons.
Personal reasons often include physical health or family reasons, while non-personal reasons are often related to the poor performance of specific business sectors under policy pressure.

The deputy general manager and vice president are the positions most likely to undergo personnel changes in pharmaceutical companies.
The fundamental reason is that the deputy general manager is mainly responsible for a specific business sector and also undertakes major business indicators.
If the performance of the indicators is consistently poor, it may be possible Affect the stability of the position of deputy general manager.

Indeed, for example, Weiming Biological issued an announcement recently that the board of directors had received a letter from the chairman of the board regarding Ding Xueguo's resignation as the general manager of the company.

The reason behind this, according to Weiming Pharmaceutical’s 2020 annual performance report released on the evening of April 14, may be the impact of its performance decline in 2020: total revenue is about 280 million yuan, a year-on-year decrease of 50.
66%; attributable to the listing The net profit of the company's shareholders was approximately -189 million yuan, a year-on-year decrease of 397.
88%.

According to the report, the main reason for the decline in performance was the continued impact of the new crown pneumonia epidemic and the repeated phases of the epidemic in various regions in the country, and the slow resumption of work by upstream and downstream enterprises, which affected operating income.

In addition, the impact of the epidemic has led to a reduction in the number of outpatient clinics at all levels of medical terminals, and the overall demand for prescription drug terminals.
In addition, the main business income has been significantly reduced compared with the previous period due to the superimposed influence of macro policies such as medical reforms and economic downturns.

In addition, because Weiming Biotechnology continued to promote marketing transformation, empowered channels, and increased investment in market expenses, sales expenses and management expenses did not drop significantly compared with the same period last year.

On the whole, changes in senior staff often imply that the company has new needs in the new situation and needs new types of talents.
For pharmaceutical professionals, opportunities and challenges coexist, and they need to adjust their development direction with the times.